方法：对48例50眼接受玻璃体腔注射bevacizumab(1.75mg)治疗的AMD患者进行回顾分析，通过常规眼科检查方法、光学相干断层扫描(OCT)、眼底荧光血管造影(FFA)和/或吲哚青绿血管造影(ICGA)等方法，观察治疗后1，3，7d； 1，6mo 最佳矫正视力(best corrected visual acuity，BCVA)、眼压、晶状体、玻璃体、黄斑中心凹厚度(central foveal thickness，CFT)和黄斑容积(total macular volume，TMV)变化，与治疗前对比分析。对注射后渗漏无明显改善或病情反复者进行眼内重复注射，所有病例都完成至少3mo的观察随访。玻璃体腔内注射avastin 1.75mg，每6wk注射一次。

结果：在48例50眼患者中，平均年龄58±20.46岁。治疗前患者的基线平均对数BCVA为0.82±0.53，CFT为364.97±151.83μm，注药后1wk虽然平均CFT和TMV没有显著改善，但BCVA有显著提高，经平均9.7mo的随访，BCVA，CFT和TMV3项指标均较基线有显著改善，终末随访时BCVA提高至少两行者为32眼(64%)，稳定者为18眼(36%)。本组患者共接受了98次玻璃体腔内注射，平均注射次数为1.98次/眼，有50%患者再注射能在术后1wk使视力提高两行或两行以上。治疗过程中未发现严重不良反应。

结论：玻璃体腔内注射bevacizumab治疗湿性AMD引起的CNV安全、副作用少，可改善患者的视功能(VA)，减轻黄斑水肿，减少CNV渗漏。但长期治疗效果需要进一步观察。

METHODS: The records of patients treated with intravitreal injection of 1.75mg bevacizumab for AMD were retrospectively reviewed. All patients were evaluated by complete ophthalmic examination, optical coherence tomography and fundus fluorescein and/or indocyanine green angiography. Observation was made on the best corrected visual acuity(BCVA), intraocular pressure, and the changes of lens, vitreous, central retinal thickness(CFT)and total macular volume(TMV), at 1d, 3d, 7d, 1mo and 6mo after the treatment and then compared with those of pre-operation. Repeated treatment with intravitreous bevacizumab occurred if there were signs of persistent or recurrent exudation. And all cases were followed up at least 6mo. An intravitreal injection of bevacizumab(1.75mg)was given once every 6wk.

RESULTS: All 50 eyes of 48 patients with the average of 58±20.46 years old were included. The mean baseline of BCVA and CFT were 0.82±0.53, and 364.97±151.83μm respectively. Although there was no significant decrease in mean CFT and TMV one week after the injection, the mean BCVA had significant improvement. At the last visit of 9.7mo follow-up, BCVA, CRT and TMV showed significant improvements over baseline values. BCVA was improved by at least two lines in 32 eyes(64%),remained stabilization in 18 eyes(36%)at the last visit. A total of 98 injections were performed and the average number of injections was 1.98 for each eye in the group. About 50% of re-injections gained at least two lines of vision improvement one week postoperatively. There were no serious adverse events during the treatment.

CONCLUSION: Intravitreal bevacizumab(avastin)injection for managing CNV due to age-related macular degeneration is safe and few side effects. Intravitreal avastin associated with improvement in visual acuity(VA), which can reduce macular edema and choroidal neovascularization leakage.But a prolonged treatment effect needs further observation.